Tango Therapeutics (TNGX) Long-Term Investments (2020 - 2021)
Tango Therapeutics (TNGX) recorded quarterly Long-Term Investments of $166.8 million in Q2 2021, little changed quarter-over-quarter from $166.8 million in Q1 2021.
Tango Therapeutics (TNGX) Long-Term Investments (2020 - 2021) Analysis & Trends
Tango Therapeutics' Long-Term Investments history runs 2 years deep, the most recent figure standing at $166.8 million for Q2 2021.
- In Q2 2021, Long-Term Investments changed N/A year-over-year to $166.8 million; the TTM figure through Jun 2021 stood at $166.8 million (changed N/A YoY), while the FY2020 annual figure was $166.8 million, changed N/A from the prior year.
- Long-Term Investments was $166.8 million for Q2 2021 at Tango Therapeutics, roughly flat from $166.8 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $166.8 million in Q4 2020 to a low of $166.8 million in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 5.17 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.75 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Tango Therapeutics | 4.05 Bn | 3.67 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 166.82 Mn |
| Mar 31, 2021 | 166.81 Mn |
| Dec 31, 2020 | 166.82 Mn |
| Sep 30, 2020 | 166.76 Mn |